Targeting CD22 for the Treatment of B-Cell Malignancies.
Targeting CD22 for the Treatment of B-Cell Malignancies.
复制标题
DOI：
10.2147/itt.s288546
复制
发表时间：
2021
影响因子：
7.2
通讯作者：
Sokol L
中科院分区：
文献类型：
--
作者：
Shah NN;Sokol L
免疫抑制剂在B细胞恶性肿瘤的治疗中发挥着越来越重要的作用。CD 19和CD 20是淋巴恶性肿瘤的常见靶点，尽管复发的患者几乎没有治疗选择。CD 22是B细胞上唯一存在的细胞表面唾液酸糖蛋白，并调节B细胞功能和增殖。因此，它是自身免疫性疾病和B细胞恶性肿瘤的有吸引力的治疗靶点。已经开发了多种靶向CD 22的疗法，包括单克隆抗体、抗体-药物缀合物、放射免疫缀合物、嵌合抗原受体T细胞和双特异性抗体。在这里，我们回顾了CD 22的生物学和淋巴系统恶性肿瘤中靶向CD 22的关键疗法。
Immunotherapeutic agents play an increasingly important role in the treatment of B-cell malignancies. CD19 and CD20 are common targets for lymphoid malignancies, though patients who relapse have few therapeutic options remaining. CD22 is a cell surface sialoglycoprotein uniquely present on B-cells and regulates B-cell function and proliferation. Thus, it is an appealing therapeutic target for autoimmune disorders and B-cell malignancies. A variety of therapies targeting CD22 have been developed, including monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, chimeric antigen receptor T cells, and bispecific antibodies. Here, we review the biology of CD22 and key therapies targeting CD22 in lymphoid malignancies.